questionText: To ask the Secretary of State for Health and Social Care, when he expects the drug Vorsidenib (Voranigo) to be made available to treat adults and children aged 12 years and over with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation.
answerText: The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations on whether new medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost e...
heading: Vorasidenib